Navigation Links
COPD Drug Via Mist Inhaler Could Raise Death Risk: Study
Date:6/14/2011

TUESDAY, June 14 (HealthDay News) -- A mist inhaler with the drug Spiriva is associated with a 52 percent increased risk of death among people with chronic obstructive pulmonary disease (COPD), a new review shows.

The mist inhaler with the soluble form of Spiriva (tiotropium) is approved in 55 countries, but is not yet approved in the United States. However, the powdered form of Spiriva is commonly used to treat COPD patients in the United States.

"Tiotropium is an inhaled drug used commonly in the treatment of COPD. Its major purpose is to reduce obstruction to airflow," explained Dr. Mark Rosen, director of pulmonary rehabilitation at North Shore University Hospital in Manhasset, N.Y., and Long Island Jewish Medical Center in New Hyde Park, N.Y.

"In the U.S., it is available only in the 'Handihaler' device that delivers the drug in a powder form," said Rosen, who was not involved in the new study. "Another form of tiotropium is available in Europe, but not the U.S., in a mist using a 'Respimat' device."

In the new study, researchers led by Dr. Sonal Singh, an assistant professor of general internal medicine at the Johns Hopkins University School of Medicine in Baltimore, analyzed the findings of five published studies that included a total of more than 6,500 patients. They compared the mist inhaler with Spiriva against a mist inhaler with a placebo.

Those who used the inhaler with Spiriva were 52 percent more likely to die than those who used the inhaler with the placebo. There was one excess death due to the mist inhaler with Spiriva for every 124 patients who were treated for a year. Cardiovascular disease is the main reason for the increased risk of death, Singh said.

"What we think is going on is that the mist inhaler is delivering a higher concentration of tiotropium than it should and that may be increasing the risk of death," Singh said in a Hopkins news release.

Rosen said that American patients need not be alarmed, but the findings should give regulators something to consider.

"It is not known why the results of the Handihaler and Respimat are so different, but [it] will give the FDA pause before approving the Respirat in this country," he said.

Another expert said Spiriva can have other serious side effects.

"While it's difficult to compare the different delivery systems' effect on mortality, it is known that certain patients with glaucoma or a history of urinary retention should not use this drug," said Dr. Len Horovitz, a pulmonary specialist at Lenox Hill Hospital in New York City. "It can also cause paradoxical bronchospasm, and severe allergic reactions. Tiotropium causes dry mouth, and can elevate heart rate. Since it is used in COPD, which is associated with cardiac conditions, other cardiac complications are possible."

Patients need to discuss the risks and benefits of COPD treatments with their doctors, Singh advised.

The study appears online June 14 in the BMJ.

COPD, the fourth leading cause of death worldwide, includes emphysema and bronchitis and is typically caused by decades of smoking.

More information

The American Academy of Family Physicians has more about COPD.

-- Robert Preidt

SOURCES: Mark Rosen, M.D., director, pulmonary rehabilitation, North Shore University Hospital, Manhasset, N.Y. and Long Island Jewish Medical Center, New Hyde Park, N.Y.; Len Horovitz, M.D., pulmonary specialist, Lenox Hill Hospital, New York City; Johns Hopkins Medical Institutions, news release, June 14, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Inhalers Linked to Higher Odds of Diabetes in Asthma, COPD Patients
2. Good Sleep Could Boost Undergrads Learning Capacity
3. Nanotubes could pose health risk to production line staff, study suggests
4. A scientific breakthrough at the IRCM could help understand certain cancers
5. Screening high-risk employees for sleep apnea could save a corporation millions of dollars
6. 1 in 5 heart-attack deaths could be prevented with new drug
7. Simple test could hold key to early diagnosis of cancers
8. MyCare -- the card that could save your life
9. Tai chi could be key to overcoming cognitive effects of chemotherapy
10. Tens of thousands of lives could potentially be saved by key heart failure therapies
11. Groundbreaking male infertility test could bring hope to millions
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
COPD Drug Via Mist Inhaler Could Raise Death Risk: Study
(Date:1/16/2017)... , ... January 16, 2017 , ... St. Louisans are well-aware of the following facts ... This year’s influenza shot seems to be having no effect on keeping this particularly ... half of the people around are coughing, sneezing, or sniffling , These ...
(Date:1/16/2017)... ... ... San Francisco dentist, Dr. Ben Amini , the founder at CitiDent, ... capable of taking digital impressions of teeth and gums. Conventional bite impressions have lagged ... , in terms of speed, efficiency and patient comfort. Increasingly, digital impressions are being ...
(Date:1/15/2017)... ... January 15, 2017 , ... Whole Health Supply, LLC is announcing the release of an ... new avenues for purchase. , The 2017 edition has wide jaws that will accommodate ... older boomers as well as diabetics. This handle is reinforced for extra strength when pressing ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock Climbing Gym is ... wraps up on the 14,000+ square foot climbing gym, the owners anticipate to open ... in New Jersey and two in New York. With this being its first location ...
(Date:1/14/2017)... ... , ... "TransFreeze Volume 3 is a self animating masking transition which allows users to reveal ... said Christina Austin - CEO of Pixel Film Studios. , TransFreeze Volume 3 provides ... clip to the next. , To use “Cut-Out First” presets, choose a video ...
Breaking Medicine News(10 mins):
(Date:1/14/2017)... , Jan. 14, 2017  Johnson & Weaver, LLP ... of purchasers of Zimmer Biomet Holdings, Inc. (NYSE: ... through October 31, 2016 (the "Class Period"). Zimmer ... and markets orthopaedic reconstructive products, such as knee and hip ... ...
(Date:1/13/2017)... Eli Lilly and Company (NYSE: ... ) announced today that the U.S. Food and Drug ... new drug application (NDA) for investigational baricitinib, a once-daily ... rheumatoid arthritis (RA). The NDA for baricitinib was submitted ... FDA extended the action date to allow time to ...
(Date:1/13/2017)... New York , January 13, 2017 ... rising prevalence of AIDS will collectively contribute to the demand ... expected to reach a value of US$ 551.0 Mn by ... will remain the most lucrative markets for western blotting, ... lead the market globally. ...
Breaking Medicine Technology: